FDA Inspection 908515 — Aurobindo Pharma USA Inc
The FDA completed an inspection of Aurobindo Pharma USA Inc on December 12, 2014 in East Windsor, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- December 12, 2014
- Fiscal Year
- 2015
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- East Windsor, NJ (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)